The Life Sciences team advised Codiak BioSciences as it closed a $76.5 million Series C financing round to advance its initial product candidates into clinical trials, and to continue to develop the company’s transformational exosome therapeutic platform. Codiak’s financing was led by existing investors ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, and Alexandria Venture Investments and were joined by new investors, including Qatar Investment Authority, Boxer Capital of the Tavistock Group, Sirona Capital, EcoR1 Capital and Casdin Capital.
Codiak BioSciences is a leader in the rapidly developing field of exosome biology. Codiak is developing a proprietary pipeline of novel, targeted medicines for diseases with high unmet medical need using its broad platform for the delivery of macromolecules to diverse cells and tissues. Its technology capitalizes on the unique properties of exosomes which have been shown to deliver nucleic acids, proteins, lipids and small molecules to various cell types.
For additional details on the financing, please read the press release.